Funding for this research was provided by:
National Health and Medical Research Council (1106870, 1063669, 1156408, 1002648, 1102752)
Cancer Australia (1044458)
National Breast Cancer Foundation (IIRS-18-137)
National Foundation for Medical Research and Innovation
Cancer Council NSW (RG-18-09)
Victorian Cancer Agency (MCRF18017)
Received: 18 February 2020
Accepted: 4 June 2020
First Online: 22 June 2020
Ethics approval and consent to participate
: cfDNA samples for this study were obtained with ethical approval from the Bellberry Human Research Ethics Committee (Application 2015-12-817-PRE-4). Patient samples for primary fibroblasts were obtained with written informed consent with human ethics approval from Monash University (2004/145) and Cabrini Hospital (03-14-04-08). Human tissue samples representing normal and tumour breast from formalin-fixed paraffin-embedded tissue were as described in Stirzaker et al. 2015 [CitationRef removed]. The study protocol was approved by the Hunter New England Research Ethics Committee (NSW HREC reference no.: HREC/09/HNE/153), Newcastle, New South Wales and Princess Alexandra Hospital Human Research Ethics Committee (PAH HREC) (research protocol: 2007/165) Brisbane, Queensland.
: Not applicable
: The authors declare that they have no competing interests.